Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc (GSK)

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,573,464
  • Shares Outstanding, K 2,508,522
  • Annual Sales, $ 43,100 M
  • Annual Income, $ 5,931 M
  • 60-Month Beta 0.73
  • Price/Sales 2.39
  • Price/Cash Flow 9.47
  • Price/Book 4.00
  • Price/Earnings ttm 12.28
  • Earnings Per Share ttm 3.34
  • Most Recent Earnings 0.25 on 02/05/20
  • Next Earnings Date 04/29/20
  • Annual Dividend & Yield 1.86 (4.54%)
  • Most Recent Dividend 0.465 on 05/14/20
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.60
  • Number of Estimates 3
  • High Estimate 0.68
  • Low Estimate 0.47
  • Prior Year 0.78
  • Growth Rate Est. (year over year) -23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.46 +1.05%
on 05/15/20
43.18 -5.30%
on 05/13/20
-1.02 (-2.43%)
since 04/22/20
3-Month
31.43 +30.10%
on 03/23/20
43.38 -5.75%
on 03/04/20
-2.19 (-5.08%)
since 02/21/20
52-Week
31.43 +30.10%
on 03/23/20
48.25 -15.25%
on 01/24/20
+0.69 (+1.72%)
since 05/22/19

Most Recent Stories

More News
Congestive Heart Failure Treatment Market Healthcare, Clinical Reviews, Survey Reports 2020

is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable)....

AZN : 55.22 (-0.11%)
BMY : 60.79 (-0.57%)
GSK : 40.89 (-0.34%)
MRK : 76.37 (-0.24%)
NVS : 84.91 (-0.09%)
VRX.TO : 30.80 (-3.33%)
Skin Cancer Treatment Market to Reach $14.55 Billion by 2027; Increasing Regulatory Approvals Will Provide Impetus to Market Growth, says Fortune Business Insights(TM)

The global skin cancer treatment market size is projected to reach USD 14.55 billion by the end of 2027. The increasing prevalence of non-melanoma cancer across the world will have a huge impact on market...

AMGN : 226.43 (+0.73%)
BMY : 60.79 (-0.57%)
GSK : 40.89 (-0.34%)
NVS : 84.91 (-0.09%)
PFE : 37.50 (+0.64%)
REGN : 569.91 (+1.59%)
Profit from the Genomics Market Momentum With These ETFs

Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.

GSK : 40.89 (-0.34%)
PBE : 58.54 (+0.53%)
ARKG : 49.56 (+2.86%)
GNOM : 16.89 (+1.38%)
IDNA : 37.01 (+1.59%)
Gilead (GILD) Gains 13% YTD on Coronavirus Drug Development

Gilead's experimental coronavirus drug, remdesivir, shows promise. The stock has been in news since the onset of the year on updates from the same.

PFE : 37.50 (+0.64%)
GILD : 73.34 (-0.22%)
GSK : 40.89 (-0.34%)
GLPG : 200.20 (-1.91%)
Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales

FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.

JNJ : 144.37 (-1.59%)
AZN : 55.22 (-0.11%)
RHHBY : 44.7000 (+0.87%)
PFE : 37.50 (+0.64%)
MRK : 76.37 (-0.24%)
GSK : 40.89 (-0.34%)
BMY : 60.79 (-0.57%)
Acute Otitis Media Treatment Market Analysis Reports Revenue Growth Globally During The Forecast Period 2019-2029

The research study on Global Acute Otitis Media Treatment market 2019 presents an extensive analysis of current Acute Otitis Media Treatment market size, drivers, trends, opportunities, challenges, as...

ABT : 91.47 (+1.19%)
BAYRY : 15.7600 (-0.91%)
LLY : 151.16 (-0.74%)
GSK : 40.89 (-0.34%)
NVS : 84.91 (-0.09%)
PDP.VN : 0.300 (+1.69%)
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio

and SONGDO, South Korea, /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung Biologics (207940.KS) have entered into a partnership to provide GSK with additional capacity to manufacture and...

GSK : 40.89 (-0.34%)
Anal Fissure Treatment Market reach the valuation of USD 2,526.5 million by the year 2023

Anal Fissure Treatment Market Research Report: by Treatment Type (Medication, Surgery), by Route of Administration (Oral, Topical), by End-user (Hospitals & Clinics, Research & Academic Institutes), and...

ABT : 91.47 (+1.19%)
AGN : 193.02 (+0.02%)
BAYRY : 15.7600 (-0.91%)
ESALF : 62.0000 (-17.88%)
GSK : 40.89 (-0.34%)
VRX.TO : 30.80 (-3.33%)
Varicella Zoster Infection Treatment Market Analysis as per the Latest Coronavirus Impact

ABT : 91.47 (+1.19%)
GSK : 40.89 (-0.34%)
NVS : 84.91 (-0.09%)
PFE : 37.50 (+0.64%)
TEVA : 11.96 (-0.50%)
VRX.TO : 30.80 (-3.33%)
Gilead, Galapagos Announce Positive Data on Inflammatory Drug

Gilead (GILD) and Galapagos announce positive data on filgotinib for the treatment of ulcerative colitis.

PFE : 37.50 (+0.64%)
GILD : 73.34 (-0.22%)
GSK : 40.89 (-0.34%)
GLPG : 200.20 (-1.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade GSK with:

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

2nd Resistance Point 41.43
1st Resistance Point 41.16
Last Price 40.89
1st Support Level 40.55
2nd Support Level 40.22

See More

52-Week High 48.25
Fibonacci 61.8% 41.82
Last Price 40.89
Fibonacci 50% 39.84
Fibonacci 38.2% 37.86
52-Week Low 31.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar